CLINICAL TRIAL

Magrolimab for Lymphoma

1 Prior Treatment
Refractory
Relapsed
Waitlist Available · 18+ · All Sexes · Stanford, CA

This study is evaluating whether a combination of two drugs may help treat Hodgkin lymphoma.

See full description

About the trial for Lymphoma

Eligible Conditions
Lymphoma, Hodgkins · Hodgkin Disease · Lymphoma · Classic Hodgkin's Lymphoma · Relapsed Classical Hodgkin Lymphoma · Refractory Classic Hodgkin Lymphoma

Treatment Groups

This trial involves 2 different treatments. Magrolimab is the primary treatment being studied. Participants will all receive the same treatment. There is no placebo group. The treatments being tested are in Phase 2 and have already been tested with other people.

Main TreatmentA portion of participants receive this new treatment to see if it outperforms the control.
PET/CT
PROCEDURE
Magrolimab
DRUG
Pembrolizumab
DRUG
Control TreatmentAnother portion of participants receive the standard treatment to act as a baseline.

About The Treatment

Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
PET/CT
2017
Completed Phase 3
~840
Magrolimab
Not yet FDA approved
Pembrolizumab
FDA approved

Eligibility

This trial is for patients born any sex aged 18 and older. You must have received 1 prior treatment for Lymphoma or one of the other 5 conditions listed above. There are 10 eligibility criteria to participate in this trial as listed below.

Inclusion & Exclusion Checklist
Mark “yes” if the following statements are true for you:
The Cockroft-Gault formula estimates creatinine clearance (CrCl) in mL/min for a given patient's body surface area (BSA) and serum creatinine (Scr) level show original
Hemoglobin ≥ 9.0 g/dL
is a predictor of good outcome Having an absolute neutrophil count of 1,000 cells/μL or more is a predictor of good outcome. show original
The text states that a person has a platelet count of at least 75,000 cells/μL. show original
This means that the total bilirubin level is less than 1.5 times the upper limit of normal show original
Age ≥ 18 years
Eastern Cooperative Oncology Group (ECOG) performance status is defined as a scale from 0 to 1 with 0 being completely healthy and 1 being so sick that you are unable to carry out any activities. show original
This text is about a biopsy that has shown that someone has relapsed or refractory cHL show original
Prior treatment with at least two systemic therapies
This text is about a specific medical condition that can be diagnosed with a certain type of imaging. show original
View All
Odds of Eligibility
Unknown<50%
Be sure to apply to 2-3 other trials, as you have a low likelihood of qualifying for this one.Apply To This Trial
Similar Trials

Approximate Timelines

Please note that timelines for treatment and screening will vary by patient
Screening: ~3 weeks
Treatment: varies
Reporting: 2 years
Screening: ~3 weeks
Treatment: Varies
Reporting: 2 years
This trial has approximate timelines as follows: 3 weeks for initial screening, variable treatment timelines, and reporting: 2 years.
View detailed reporting requirements
Trial Expert
Connect with the researchersHop on a 15 minute call & ask questions about:
- What options you have available- The pros & cons of this trial
- Whether you're likely to qualify- What the enrollment process looks like

Measurement Requirements

This trial is evaluating whether Magrolimab will improve 1 primary outcome, 1 secondary outcome, and 1 other outcome in patients with Lymphoma. Measurement will happen over the course of 4 months.

Magrolimab related Adverse Events
4 MONTHS
Magrolimab safety and tolerability will be assessed on the basis of magrolimab related adverse events occurring within 4 cycles of treatment (4 months). The outcome will be reported as the number of magrolimab related adverse events judged mild (Grade 1), moderate (Grade 2), severe (Grade 3), life threatening (Grade 4), or fatal (Grade 5), numbers without dispersion.
4 MONTHS
Overall Response (OR)
8 MONTHS
Overall response (OR) is defined as the sum of participants who achieve a complete response (CR) plus the number of participants who achieve a partial response (PR). Treatment response will be assessed per the Lugano criteria (aka the Cheson criteria). The criteria are: CR: Complete disappearance of all lesions, evidence, and effects of disease PR: ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD): less than PR. Progressive disease (PD): sum of the product of dimensions (SPD) of lesions increased ≥50% from smallest value The outcome will be reported as the number of participants with either a CR or a PR after 4 and 8 cycles of treatment (4 and 8 months). For participants who undergo a subsequent stem cell transplant, the value will be recorded as the time to transplant (censored).
8 MONTHS
Complete Response (CR)
2 YEARS
Each participant's response to treatment will be assessed per the Lugano criteria. The criteria are: Complete Response (CR): Complete disappearance of all lesions, evidence, and effects of disease Partial Response (PR): ≥50% decrease in SPD of the 6 largest lesions with no increase in the size of the other nodes; splenic / hepatic nodules regress ≥50%, and with no new sites of disease Stable disease (SD): less than PR. Progressive disease (PD): sum of the product of dimensions (SPD) of lesions increased ≥50% from smallest value The outcome will be reported as the number of participants with a CR after 4 and 8 cycles of treatment (4 and 8 months), and if CR is achieved anytime within 2 years ("overall").
2 YEARS

Patient Q & A Section

Please Note: These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

What are common treatments for lymphoma?

Lymphoma is often treated with curative intent with chemotherapy. Radiation therapy has become less common in the last decade, and the majority of patients with Stage 2 and Stage 3 disease now receive chemotherapy solely. Lymphoma is rare, with an overall rate of less than 1 per 1,500 persons per year. These data are similar to those of cancer as a whole.

Anonymous Patient Answer

Can lymphoma be cured?

Can lymphoma be cured? The treatment options and prognosis are highly influenced by stage and age. Survival is strongly influenced by comorbid disorders as well as stage. Treatment options have improved significantly over the last decade. Chemotherapy and radiotherapy are the mainstay of the treatment options, which are well tolerable. For people with Stage IV lymphoma, the prognosis is generally poor, resulting in a median 5-year survival rate of 17% and a mean 5 year survival rate of 23%. This low survival can be improved by optimizing the treatment modalities over and above the more traditional treatment options.

Anonymous Patient Answer

What are the signs of lymphoma?

Signs that could signify a diagnosis of lymphoma include recent onset of enlarged lymph nodes, high levels of abnormal white blood cells, and pain in and around the lymph nodes. Abnormalities on a complete blood count (C&S) may indicate the possibility of non-Hodgkin lymphoma. Abnormalities on an erythrocyte sedimentation rate (ESR) may also indicate a possibility of lymphoma. Other types of lymphomas have similar signs and symptoms. This article presents a more detailed overview of specific diagnoses than those listed herein.

Anonymous Patient Answer

What is lymphoma?

Lymphomas are a group of cancers that derive from cells of the lymphoid lineages (lymphocytes, granulocytes, and B cells). They are characterized by the inability to fight infection and cancer prevention. Tumors from multiple lymphoid lines comprise approximately 70% of NHLs. Lymphomas may be primary, i.e., arising from blood cells and originating in the tissue, or secondary cancers, i.e., arising from neoplasms such as a leukaemia (a cancer of the blood).

Anonymous Patient Answer

How many people get lymphoma a year in the United States?

Lymphoma is the third most common cancer overall among people 18–64 years (about 250,000 persons every year) in the United States. Its incidence in men is about 2.3 times higher than that in women; among people over 65, it is a little less common. These data, when combined, mean that in the United States about 4 percent of all people suffer from lymphoma yearly.

Anonymous Patient Answer

What causes lymphoma?

Lymphoma is multifactorial disease, and the many genes and environmental factors that influence lung cancer and SLE are likely to exert effects on lymphomagenesis in the same manner.

Anonymous Patient Answer

Have there been other clinical trials involving magrolimab?

Patients with CD30+ Hodgkin's lymphoma have received and responded well to treatment with the monoclonal antibody monoclonal to CD30. However, the therapeutic effect of this antibody in relapsing CD30- lymphoma, in which CD30 is undetectable, appears to be variable with the results of previous clinical trials having been varied; as of 2006, however, there remains no evidence that the addition of monoclonal antibodies to a standard of care regimen for relapsing patients with indolent mycosis fungoides effectively alters disease course or alters relapsing/refractory disease.

Anonymous Patient Answer

What are the common side effects of magrolimab?

This drug has been tested in a single phase III study and the most common side effects detected during this study were headache (10%), nausea (5%), fatigue (6%), itchiness (6%), constipation (2%) and abdominal pain (2%). Other side effects observed in the general population include dizziness, heart palpitations and increased urination. In clinical trials the most common side effects detected were headache (10%), fatigue (8%), nausea (7%), constipation (5%), itchiness (5%) abdominal pain (3%), back pain (2%), urinary irritation (2%) and insomnia (2%).

Anonymous Patient Answer

Does lymphoma run in families?

Patients with lymphoma demonstrate genetic heterogeneity in their malignant cells. There is limited concordance of clinical features between familial and sporadic cases, but some evidence for familial risk factors. There is no evidence that the familial clustering is of recent descent; therefore, it is likely that the observed clustering is due to genetic factors and not related to disease-related risk or to environmental factors.

Anonymous Patient Answer

What are the chances of developing lymphoma?

The current data show that the overall chance of the development of lymphoma can be estimated by a Poisson distribution. Therefore, the risk of developing lymphoma does not differ significantly if a person lives longer or shorter.

Anonymous Patient Answer

How quickly does lymphoma spread?

Lymphoma spreads to the nodes, bone marrow, liver, lungs, spleen, brain, spinal cord, or kidney. Spread may be measured by CT scan, PET, or MRI. Lymphoma spreads slowly, even in stage I disease, but may not be diagnosed until extensive spread occurs in stage II disease. Lymphoma tends to be diagnosed later than it actually occurred because it is very often asymptomatic. There is more dissemination in stage IV than in any other tumor sub-system. Spread rate in stage IV disease cannot be determined, as it is often too far developed for the diagnosis to be definitively made. In patients over 80, dissemination is more rapid and may have a rapid effect on survival.

Anonymous Patient Answer

What is the average age someone gets lymphoma?

This information can be useful in estimating the life expectancy among lymphoma patients. It can help calculate the average number of cases per year per 100,000 in a large population. In other words, this information is useful in getting to understand, and eventually treat, the disease more efficiently.

Anonymous Patient Answer
See if you qualify for this trial
Get access to this novel treatment for Lymphoma by sharing your contact details with the study coordinator.